Atossa Therapeutics Inc. [NASDAQ: ATOS] jumped around 0.14 points on Monday, while shares priced at $1.10 at the close of the session, up 14.70%. The company report on January 8, 2021 that COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven Quay.
Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS ), recently shared his latest research and findings regarding the origins of COVID-19 and the manner in which it spread so quickly.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
“Looking at the origins of the virus is crucial to understand how it infects humans and to develop better treatments.”.
Atossa Therapeutics Inc. stock is now 15.79% up from its year-to-date (YTD) trading value. ATOS Stock saw the intraday high of $1.10 and lowest of $0.932 per share. The company’s 52-week high price is 5.08, which means current price is +25.71% above from all time high which was touched on 01/05/21.
Compared to the average trading volume of 4.33M shares, ATOS reached a trading volume of 28708382 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Atossa Therapeutics Inc. [ATOS]?
Maxim Group have made an estimate for Atossa Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Average True Range (ATR) for Atossa Therapeutics Inc. is set at 0.12 The Price to Book ratio for the last quarter was 1.21, with the Price to Cash per share for the same quarter was set at 0.21.
How has ATOS stock performed recently?
Atossa Therapeutics Inc. [ATOS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.79. With this latest performance, ATOS shares gained by 26.18% in over the last four-week period, additionally sinking by -67.26% over the last 6 months – not to mention a drop of -29.94% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 51.55, with the RSI for the last a single of trading hit 58.73, and the three-weeks RSI is set at 46.89 for Atossa Therapeutics Inc. [ATOS]. The present Moving Average for the last 50 days of trading for this stock 1.2594, while it was recorded at 1.0137 for the last single week of trading, and 2.3109 for the last 200 days.
Atossa Therapeutics Inc. [ATOS]: Deeper insight into the fundamentals
Return on Total Capital for ATOS is now -156.88, given the latest momentum, and Return on Invested Capital for the company is -156.92. Return on Equity for this stock declined to -157.00, with Return on Assets sitting at -131.50. When it comes to the capital structure of this company, Atossa Therapeutics Inc. [ATOS] has a Total Debt to Total Equity ratio set at 0.38. Additionally, ATOS Total Debt to Total Capital is recorded at 0.38, with Total Debt to Total Assets ending up at 0.35. Long-Term Debt to Equity for the company is recorded at 0.09, with the Long-Term Debt to Total Capital now at 0.08.
Reflecting on the efficiency of the workforce at the company, Atossa Therapeutics Inc. [ATOS] managed to generate an average of -$2,873,296 per employee.Atossa Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.20 and a Current Ratio set at 7.20.
Earnings analysis for Atossa Therapeutics Inc. [ATOS]
With the latest financial reports released by the company, Atossa Therapeutics Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.33/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATOS.
Insider trade positions for Atossa Therapeutics Inc. [ATOS]
There are presently around $1 million, or 6.50% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: VANGUARD GROUP INC with ownership of 208,896, which is approximately 73.086% of the company’s market cap and around 0.12% of the total institutional ownership; MORGAN STANLEY, holding 131,557 shares of the stock with an approximate value of $0.14 million in ATOS stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $99000.0 in ATOS stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Atossa Therapeutics Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 16 institutional holders increased their position in Atossa Therapeutics Inc. [NASDAQ:ATOS] by around 444,013 shares. Additionally, 4 investors decreased positions by around 21,049 shares, while 4 investors held positions by with 256,018 shares. The mentioned changes placed institutional holdings at 721,080 shares, according to the latest SEC report filing. ATOS stock had 12 new institutional investments in for a total of 222,089 shares, while 1 institutional investors sold positions of 100 shares during the same period.